Abstract
Objective: The aim of the study was to make a further evaluation of Ginsenoside Rg3. Methods: The clinical effects of the drug on moderate and advanced lung cancer, including side effects, were observed. Results: Ginsenoside Rg3 improved chemotherapy significantly. The clinical relief rate of patients treated with antiangiogenic agent 20 (R)-Ginsenoside Rg3 was 36.6%, which was higher than that of the patients not treated with it (16.7%) (P <0.05). It had no significantly different effects on lung cancers of different types of tissues (P>0.05). It provided better treatment on the cancer at early stage than that at advanced stage (P<0.05). Moreover the living qualities of the patients were improved notably (P<0.05). Conclusion: Combined with chemotherapy, angiogenesis inhibitor-20(R)-Ginsenoside Rg3 can improve clinical therapeutic efficacy and the living qualities of patients significantly.
| Original language | English |
|---|---|
| Pages (from-to) | 176-178+192 |
| Journal | Academic Journal of Xi'an Jiaotong University |
| Volume | 15 |
| Issue number | 2 |
| State | Published - Nov 2003 |
| Externally published | Yes |
Keywords
- Ginsenoside Rg3
- Lung neoplasma
- Neovascularization
